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1 Chemokine expression and function was monitored in an experimental model of granulomatous
tissue formation after injection of croton oil in complete Freund's adjuvant (CO/CFA) into mouse
dorsal air-pouches up to 28 days.
2 In the ®rst week, mast cell degranulation and leukocyte in¯ux (mononuclear cell, MNC, and
polymorphonuclear cell, PMN) were associated with CXCR2, KC and macrophage in¯ammatory
protein (MIP)-2 mRNA expression, as determined by TaqMan1 reverse transcriptase-polymerase
chain reaction. KC (*400 pg mg protein71, n=12) and MIP-2 (*800 pg mg protein71, n=12)
proteins peaked at day 7, together with myeloperoxidase (MPO) activity. Highest MIP-1a (41 ng
mg protein71, n=12) levels were measured at day 3.
3 After day 7, a gradual increase in CCR2 and CCR5 mRNA, monocyte chemoattractant protein
(MCP)-1 mRNA and protein expression was measured. MCP-1 protein peaked at day 21 (*150 pg
mg protein71, n=12) and was predominantly expressed by mast cells. A gradual increase in N-
acetyl-b-D-glucosaminidase (NAG) activity (maximal at 28 days) was also measured.
4 An antiserum against MIP-1a did not modify the in¯ammatory response measured at day 7
(except for a 50% reduction in MIP-1a levels), but provoked a signi®cant increase in MPO, NAG
and MCP-1 levels as measured at day 21 (n=6, P50.05). An antiserum to MCP-1 reduced NAG
activity at day 21 but increased MPO activity values (n=8, P50.05).
5 In conclusion, we have shown that CO/CFA initiates a complex in¯ammatory reaction in which
initial expression of MIP-1a serves a protective role whereas delayed expression of MCP-1 seems to
have a genuine pro-in¯ammatory role.
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Introduction
The initial phases of the host in¯ammatory response are
characterized by the synthesis and release of several soluble
mediators both peptidic and non-peptidic in nature. In
particular, multi-potent cytokines such as interferon-g, inter-
leukin (IL)-1, IL-4 or tumour necrosis factor (TNF)-a activate
cells adjacent to the site of injury, including resident leukocytes
(macrophages and mast cells), endothelial cells and interstitial
®broblasts (Smith et al., 1997; Paul & Seder, 1994).
Chemotactic factors are then generated to promote extravasa-
tion of blood-borne leukocytes (Gao et al., 1997; Luster, 1998).
Amongst the latter group of mediators, an important role is
occupied by chemokines.
Chemokines are low molecular weight proteins classi®ed
according to the presence or absence of an amino acid between
the ®rst two cysteines, yielding CXC chemokines and CC
chemokines (Baggiolini, 1998), or CXCL and CCL chemokines
according to a more recent nomenclature (Zlotnik & Yoshie,
2000). CXC chemokines act predominantly on neutrophils and
T lymphocytes, whereas CC chemokines are able to chemoat-
tract monocytes, T lymphocytes, eosinophils, basophils,
dendritic cells and NK cells, depending on the speci®c protein
(Mantovani, 1999). In the mouse, examples of CXC chemo-
kines are KC (CXCL1) and macrophage in¯ammatory protein
(MIP)-2 (CXCL2), whereas monocyte chemoattractant protein
(MCP)-1 (or CCL2), MIP-1a (or CCL3), regulated on activated
normal T cell expressed and secreted (RANTES or CCL5) and
eotaxin (CCL11) belong to the CC chemokine group (Furie &
Randolph, 1995; Luster, 1998). The distinction among the
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chemokine sub-groups is maintained also with respect to the
receptor(s) they activate on target cells. CXCR are activated by
CXC chemokines with a certain degree of promiscuity. CCR
also share more than one chemokine (Premack & Schall, 1996;
Zlotnik & Yoshie, 2000). For instance, CXCR2 can be
activated by KC, MIP-2 or LPS-induced CXC chemokine
(LIX or CXCL5), whereas CCR5 binds MIP-1b (CCL4) and
RANTES with comparable anities (Premack & Schall, 1996;
Murphy et al., 2000).
The speci®city of chemokine actions suggests a key role in the
co-ordination of a range of in¯ammatory responses. The
expression and biological actions of a given chemokine
provides a rationale for the predominance of distinct leukocyte
subsets in dierent in¯ammatory pathologies and the develop-
ment of selective chemokine receptor antagonists is a rational
approach for the discovery of novel anti-in¯ammatory
molecules (Murphy et al., 2000). This line of research may
lead to novel therapies for asthma, characterized by eosinophil
in¯ux, as well as rheumatoid arthritis, where neutrophil in¯ux
into the aected joint occurs during the acute phases of the
disease (Kunkel et al., 1996; Ward, 1997).
Few studies have investigated chemokine roles in long term
models of chronic in¯ammation. For instance, the expression of
MIP-2 and MIP-1a in a murine model of arthritis has been
reported to be associated with development of the disease
(Kasama et al., 1995). A more recent study has investigated the
time-dependencyofmRNAexpression for several chemokines in
themodelofcollagen-inducedarthritis (Thorntonetal., 1999). In
a separate study,MCP-1 has been shown to have a central role in
models of lung granuloma, with a preference towards those
driven by a Th2 lymphocyte response (Chensue et al., 1996).
In the present study we have used a model of murine
granulomatous in¯ammation. Injection of a mixture of croton
oil in complete Freund's adjuvant (CO/CFA) into a preformed
dorsal air-pouch induces an intense in¯ammatory reaction
associated with granuloma formation (Kimura et al., 1985;
1986). A putative `in¯ammatory phase' characterized by
neutrophil in¯ux and expression of pro-in¯ammatory cytokines
such as IL-1a, IL-1b and tumour necrosis factor-a occurs
within the ®rst week of in¯ammation (Appleton et al., 1993).
This is followed by a putative `repair phase' characterized by
expression of anti-in¯ammatory cytokines (e.g. transforming
growth factor-b) and occurs from day 14 onwards (Appleton et
al., 1993). We have used this model to investigate the expression
of selected CXC and CC chemokines and chemokine receptors,
at the level of transcription and translation, together with
quanti®cation of the recruitment of distinct cell types during
the dierent stages of the in¯ammatory reaction. A neutralizing
strategy has been used to address the speci®c role that the
chemokine MIP-1a and MCP-1 may be playing in the context
of this complex in¯ammatory reaction.
A succinct account of this work has been presented at two
recent meetings of the British Pharmacological Society
(Carollo et al., 1999; 2000).
Methods
Animals
Female Swiss Albino mice (28 ± 30 g body weight) were
purchased from Banton and Kingsman (Hull, U.K.) and
maintained on a standard chow pellet diet with tap water ad
libitum. Animals were grouped at eight per cage in a room
with controlled lighting (lights on 0800 h, o 2000 h) and
temperature (21 ± 238C), and used 2 ± 3 days after their
arrival. Animal work was performed according to Home
Oce regulations (guidance on the operation of the Animals,
(Scienti®c Procedures) Act 1986, United Kingdom).
Chronic granulomatous inflammation
The granulomatous air-pouch model was performed as
described in the studies by Kimura et al. (1995; 1986) and
Appleton et al. (1993). Brie¯y, air pouches were formed by
sub-cutaneous (s.c.) injection of 3 ml of air into the dorsal
subcutaneous tissue. After 24 h (day 0), in¯ammation was
induced by injection of 0.5 ml of 0.1% v v71 croton oil in
complete Freund's adjuvant containing 5 mg ml71 Myco-
bacterium tuberculosis (CO/CFA) (Sigma-Aldrich Company
Ltd, Poole, Dorset, U.K.) (Kimura et al., 1985; 1986;
Appleton et al., 1993; Colville-Nash et al., 1995). In some
cases, 0.5 ml of incomplete Freund's adjuvant (IFA) alone
were injected (Sigma-Aldrich) as a negative control group.
A group of untreated animals was also added. At several
days post-injection (days 3, 7, 14, 21, and 28), animals
were sacri®ced by CO2 exposure and the whole air-
pouches removed. The upper part of the granuloma was
dissected together with the skin and used for histology (see
below). The lower part of the granuloma was divided into
three fragments, snap frozen and stored at 7808C prior to
biochemical determinations (see below). In a few cases, the
whole lower part of the granuloma was collected and its
wet weight determined. Previous studies have demonstrated
that the biochemical and histological characteristics of the
upper and lower parts of the granuloma are identical
(Appleton et al., 1993).
Preparation and analysis of tissue sections by histology
The skin and granuloma samples (upper part) were divided
into three portions and ®xed with dierent procedures
speci®c for cryostat, paran or historesin sections.
Cryostat sections Tissues were snap-frozen in cold isopen-
tane (BDH Laboratory Supplies, Poole, Dorset, U.K.), ®xed
in O.C.T. compound (BDH Laboratory Supplies), and 10 mm
sections cut in a cryostat, mounted on 3-aminopropyl-
triethoxy-silane coated slides (BDH Laboratory Supplies)
and stored at room temperature.
Paran sections Tissue samples were ®xed in 3% paraf-
ormaldehyde and 0.5% glutaraldehyde (TAAB Laboratories,
Aldermaston, Berkshire, U.K.) in sodium cacodylate buer
(pH 7.4) for 24 h. Tissues were embedded in paran and
3 mm sections cut on an ultramicrotome (Reichert Ultracut;
Leica, Austria), thereafter dewaxed with xylene and rehy-
drated through graded concentrations of ethanol.
Historesin sections Following ®xation in 3% paraformalde-
hyde and 0.5% glutaraldehyde (TAAB Laboratories), in
sodium cacodylate buer (pH 7.4) for 24 h, and embedding
in historesin (Technovit 7200, UnicrylTM, TAAB Labora-
tories), 1.5 mm sections were made and stained with May-
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Grumwald (1 : 2) and Giemsa (1 : 10) (BDH Laboratory
Supplies).
Immunohistochemistry
Cryostat and paran sections were ®xed in acetone and re-
hydrated in 10 mM phosphate-buered saline (PBS, pH 6.0).
Endogenous peroxidases were quenched with 1% H2O2
(30% v v71) in methanol, prior to blocking non-speci®c
binding with normal goat serum (Vectastain1 ABC Kit,
Vector Laboratories, Bretton, Peterbourough, U.K.) diluted
1 : 50 in PBS supplemented with 0.1% BSA (Sigma-Aldrich).
Sections were incubated overnight at 48C with a polyclonal
rabbit anti-mouse MIP-1a (®nal dilution of 1 : 2000) or a
polyclonal rabbit anti-mouse MCP-1 (®nal dilution of
1 : 1000), respectively. Both antibodies have been produced
at the University of Michigan Medical School, and have been
previously used to monitor the expression of these chemo-
kines in murine models of in¯ammation (Chensue et al.,
1996; DiPietro et al., 1998; Kunkel et al., 1996; Standiford et
al., 1995). A non-immune rabbit serum (Sigma-Aldrich) was
used as a negative control. Another control was represented
by the anti-MCP-1 serum pre-absorbed (24 h, 48C) with 1 mg
mouse MCP-1 (R&D Systems, Abingdon, Oxon, U.K.). In all
cases, tissues were counter-stained with 0.25% toluidine blue
in 0.25% Michaelis' veronal acetate-hydrochloric acid buer
(pH 4.5) or Harris' haematoxylin (BDH Laboratory Sup-
plies). Sections were air-dried and mounted in DPX (BDH
Laboratory Supplies) prior to observation by light micro-
scopy using an Olympus BH-2-RFCA microscope. The anti-
MIP-1a antibody did not react with paran sections, whereas
the anti-MCP-1 antibody reacted with both cryostat and
paran sections.
Semi-quantitative analysis of cell influx by histology
Historesin sections were used for morphological analysis of
tissues obtained from IFA treatment and to determine cell
number in granuloma tissues (after injection of CO/CFA)
throughout the entire time course. Using a high power
objective (magni®cation, 6600) cells were counted in three
areas of approximately 100 mm2, using ®ve distinct serial
sections (15 mm of space between each section) for two
dierent animals by an observer unaware of the treatments.
The degree of PMN (590% neutrophils) and MNC
(lymphocytes and monocytes/macrophages) in®ltration as
well as the presence of mast cells (intact or degranulated)
were determined in the dierent areas of the skin and in the
granuloma. The number of ®broblasts was also monitored.
Data are reported as number of cells per 1006100 mm2 of
tissue area.
Biochemical determinations
Detection of chemokine levels by ELISA Samples were
placed in lysing buer (1% P-40 Nonidet, 500 mM NaCl,
50 mM HEPES, 20 mg/ml leupeptin) (Standiford et al., 1995)
at an approximate ratio of 10 mg ml71 and homogenized
using a T25 IKA Labortechnik homogenizer (Staufen,
Munich, Germany). Chemokine levels were measured in
tissue supernatants using commercially available ELISA kits
for mouse MIP-1a, MIP-2, KC and RANTES (R&D
Systems, Abingdon, Oxon, U.K.) and MCP-1 (Biosource
International, Camarillo, CA, U.S.A.).
Enzymatic activities Myeloperoxidase (MPO) and N-acetyl-
b-D-glucosaminidase (NAG) activity in tissue supernatants
were determined as an indirect measurement of neutrophil and
monocyte in¯ux (Bailey et al., 1982; Mullane et al., 1985).
The MPO reaction was performed in 200 ml total volume
using 2 mM 3,3',5,5'-tetramethyl-benzidine (Sigma-Aldrich)
in 50 mM acetate buer (pH 6) as a substrate, and hydrogen
peroxide (20 ml of a solution 30% v v71). After 30 min at
room temperature, absorbance was read at 620 nm
wavelength and interpolated on a standard curve constructed
with 0 ± 2000 mu l71 human neutrophil MPO (Calbiochem,
Beeston, Nottingham, U.K.). Data are expressed as mu mg
protein71.
The NAG reaction was performed in 250 ml total volume
containing unknown sample and the substrate p-nitrophenyl-
N-acetyl-b-D-glucosaminide (2.5 mM in 50 mM citrate buer,
pH, 4.5) (Sigma-Aldrich). After 45 min incubation at 378C,
the reaction was initiated by adding 100 ml of glycine buer
(0.2 M, pH 10.4; BDH Laboratory Supplies). Readings at
405 nm wavelength were interpolated on a standard curve
constructed with p-nitrophenol (0 ± 500 nmol ml71) (Sigma-
Aldrich). Data are reported as nmol of products formed mg
protein71.
Protein concentration in the homogenized tissue samples
was determined by the Bradford assay (Biorad Protein Assay,
BioRad Laboratories GmbH, Munchen, Germany).
TaqMan1 reverse-transcriptase-polymerase chain
reaction (RT ±PCR) analysis
TaqMan real-time RT±PCR assay allows reliable, reprodu-
cible and accurate measurement of mRNA expression
following activation of a given gene (Gibson et al., 1996;
Heid et al., 1996; Hirayama et al., 1998; Lie & Petropoulos,
1998; Orlando et al., 1998). Here, this technique was applied
to monitor chemokine and chemokine receptor expression.
Total RNA was extracted from pooled samples of skin or
granuloma tissue (n=5±10), following homogenization with
a T25IKA Labortechnik homogenizer pre-sterilized in a bath
of Trigene1 solution (2%) overnight. To avoid contamina-
tion, the homogenizer was cleaned with ethanol, Trigene1
solution and sterile water between each tissue sample. The
RNA yield and purity was determined by the A260/A280 ratio
and the integrity of total RNA extracted was con®rmed by
the presence of 28S and 18S bands following electrophoresis
on a 1% agarose gel. RNA was further puri®ed by selective
precipitation, using RNeasy1 mini-spin columns (QIAGEN,
Crawley, West Sussex, U.K.) and stored at 7808C until use.
cDNA was synthesized using Superscript II kit (GIBCO-
BRL, Life Technologies Ltd, Paisley, Scotland, U.K.), with
2 mg of total RNA being converted into cDNA by addition
of 1 ml of Superscript II reverse transcriptase (RTEnzyme1,
10,000 ± 50,000 units ml71) (GIBCO-BRL). Negative controls
were obtained by reverse transcriptase omission. A standard
curve to calculate relative amounts of transcript in unknown
samples was constructed using cDNA generated from the
lymph nodes of oxazolone-treated mice.
TaqMan1 ¯uorogenic probes used were -FAM (6-carboxi-
¯uorescein; emission 1538 nm) or -JOE (6-carboxy-4,5-
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dichloro-2,7-dimethoxy¯uorescein; emission 1546 nm) repor-
ter and TAMRA (6-carboxytetramethylrodamine; emission
1582 nm) quencher dyes (Applied Biosystems, Foster City,
CA, U.S.A.). Primers and probes were designed in
accordance to the `guidelines for designing TaqMan1
¯uorogenic probes for 5' nuclease assay' (provided by Perkin
Elmer Applied Biosystems). Primers were obtained from
Genosys (Sigma-Genosys Ltd, Pampisford, Cambridgeshire,
U.K.) and optimized using a standard cDNA template. Table
1 summarizes the sequences of the probes and primers used.
TaqMan1 reactions were set up as indicated by the
manufacturers and ampli®ed using the ABI PRISM 7700
Sequence Detection System. cDNA prepared from granuloma
samples was diluted 1/10 and tested in duplicate or triplicate
in the TaqMan1 RT±PCR assay. Primers and probes were
also designed for MIP-1a and CCR1 and tested without
success.
For each well a mixture of forward and reverse primers,
probes and TaqMan1 Master Mix (AmpliTaq Gold DNA
Polymerase, AmpErase UNG, dNTPs with dUTP) (GIBCO
BRL) was added (see Table 2 for the optimal ratios). Cycling
conditions for the TaqMan1 PCR reactions were as follows:
2 min at 508C, 10 min denaturation at 958C, 15 s annealing
at 958C and 1 min extension at 608C. For data handling, a
standard curve was constructed from a scatter plot of log
dilution factor vs the corresponding threshold cycle (CT) and
used to calculate the relative abundance of each target gene
in each sample. 18S CT values were used to correct for the
amount of cDNA in each sample and give a normalized
relative amount for each sample.
Treatment with neutralizing antisera
The same antisera used for immunocytochemistry of MIP-1a
and MCP-1 were also used for assessing the function in vivo
that either chemokine might have. Both rabbit sera have been
validated for the respective chemokine in vitro and in vivo
assays (Chensue et al., 1996; DiPietro et al., 1998; Kunkel et
al., 1996; Standiford et al., 1995).
The anti-MIP-1a rabbit serum, or non-immune rabbit
serum (Sigma-Aldrich), were given i.p. at the dose of 0.5 ml
per mouse (Di Pietro et al., 1998) per injection on days 71,
+1 and +4, with CO/CFA being injected into the air-pouch
at day 0. Animals were sacri®ced at days 7 or 21, since these
times corresponded approximately to the peaks of the MIP-
1a and MCP-1 protein levels.
The anti-MCP-1 rabbit serum has been used shown to be
active in a murine model of lethal endotoxemia (Zisman et
al., 1997). Its activity has also been shown in a model of
granuloma formation in which repeated injections decreased
the size of the granuloma by about the 30% (Chensue et al.,
1996). Since the peak of MCP-1 occurred at day 21, the
antibody, or non-immune rabbit serum, were given i.p. at the
dose of 0.5 ml per mouse on days 10 and 14, and animals
sacri®ced on day 21.
In both cases a series of biochemical determinations in the
granuloma samples was made.
Statistics
Dierences among groups were analysed using ANOVA plus
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parametric Kruskal-Wallis analysis was used for TaqMan1
data. InstatTM software was run on an Apple Macintosh G3.
Results
CO/CFA, but not IFA, injection provokes granuloma
formation
CO/CFA injection produced formation of granulomatous
tissue already detectable at day 3. The tissue wet weight
increased in a time dependent manner until day 7, decreasing
thereafter (Figure 1). In contrast, IFA injection did not produce
formation of granuloma, and the weight of the tissue did not
signi®cantly change throughout the entire time course.
These dierences were con®rmed by histology. IFA caused
only a large increase in the thickness of the adipose tissue
(Figure 2A illustrates the morphology at day 14) when
compared to the skin of control mice (Figure 2B). CO/CFA
produced a series of time-dependent changes illustrated from
Figure 2C to G. On day 3, the presence of the granulomatous
tissue under the skeletal muscle layer was detected (Figure
2C). The thickness of the granuloma doubled by day 7
(Figure 2D), with a similar appearance at day 14 (Figure 2E).
A contraction of the granulomatous tissue, replaced by
®brotic tissue mainly formed by collagen, was observed on
day 21 (Figure 2F). A similar pattern was observed at day 28
(Figure 2G).
The majority of the cells in the granuloma were PMN
and MNC. Fibroblasts could also be seen, whereas mast
cells were predominantly found in the skin layers. The
localization and the numbers of the dierent cells varied
throughout the time-course (Figure 3). An increase in
MNC was observed by day 7 in the granulomatous layer,
decreasing by days 14 to 21, thereafter increasing again at
day 28 (Figure 3D). The same pro®le was detected in the
adipose tissue (Figure 3B), but not in the dermis and in
the skeletal muscle layer, where MNC in®ltration de-
creased from day 7 onwards (Figure 3A,C). Similar
changes were detected in PMN in¯ux throughout the
tissue layers: following a peak at day 7 and a time-
dependent reduction by day 21, a second phase of in¯ux
into the granulomatous and adipose tissue layers was
apparent at day 28 (Figure 3). However, the changes in
the granuloma were more pronounced with PMN and
MNC counts, 5 ± 10-fold higher than those counted in the
skin layers. An approximate 2 ± 3-fold increase in mast cell
numbers was measured in all tissue layers by days 7 and
14 post-in¯ammation, 50% of which were degranulated
(data not shown). Detection of cells became dicult by
day 21 in the skeletal muscle tissue probably because of
Table 2 Concentration and optimal ratio of genes of interest
Gene of PROBE Forward primer Reverse primer Optimal ratio
interest (pmol ml71) (pmol ml71) (pmol ml71) (nM)
CXCR2 5 4.7 10.8 300:300
CCR2 5 4.7 9.3 300:300
CCR5 5 12.8 11.4 300:300
KC 5 10 10 300:300
MIP-2 5 10 10 900:900
LIX 5 100 100 900:300
MCP-1 5 10.3 13.2 300:300
MPC-3 5 12.9 9.2 300:300
MIP-1b 5 11.4 11.1 50:50
RANTES 5 6.4 12.6 50:50
Shown are the concentrations of probes and primers and the optimal ratios, in relation to CT values, as used for TaqMan
1 analysis.
Figure 1 Time-course of granuloma weight after CO/CFA or IFA
injection into murine air-pouches. Change in the weight of in¯amed
tissue after local injection of 0.5 ml IFA or CO/CFA mixture. Note
that granuloma formation occurs only after CO/CFA injection (see
Figure 2). Data are mean+s.e.mean of eight mice per group.
*P50.05 vs day-3 group.
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the replacement of this tissue with the ®brotic ®bres
(Colville-Nash et al., 1995). Fibroblast cell numbers
increased in the granulomatous tissue from day 14 onward
with highest values at day 28 (Figure 3).
Figure 2 Histological features of in¯amed tissues after CO/CFA or IFA injection into murine air-pouches. (A): May-Grumwald-
Giemsa staining of sections (1.5 mm) obtained from historesin embedded tissues, showing morphology of the air-pouch 14 days after
IFA injection. (B) to (G): toluidine blue staining on cryostat sections (10 mm). In (B) skin morphology of an untreated mouse, with
the epidermal layer (e), the dermis (d), the subcutaneous tissue (or hypodermis) consisting mainly of adipose tissue (a), represented
by white globular cells and skeletal muscle cells (sk), stained in light blue. From (C) to (G) the response to CO/CFA injection. On
day 3 (C), granulomatous tissue (g) can be localized under the skeletal muscle layer (sk), with increased thickness on day 7 (D) and
day 14 (E). Proliferation of ®brotic tissue (not shown with this staining) and reduction of granuloma tissue occurred between day 21
(F) and day 28 (G). Pictures are representative of 10 distinct analyses. Bar, 150 mm.
British Journal of Pharmacology vol 134 (6)
MIP-1a and MCP-1 expression and role in experimental granulomaM. Carollo et al 1171
Enzymatic activities in the granuloma
MPO activity increased rapidly (*30 mu mg protein71 per
day) up to day 7 post-CO/CFA injection (Figure 4A). In line
with histological quanti®cation, lower MPO values were
measured at days 14 and 21, with a subsequent increase at
day 28 (Figure 4A). High MPO values clearly corresponded to
PMN in®ltration, as seen in Figure 4C. NAG activity followed
a dierent pro®le, with values above skin controls from day 7,
and a time-dependent increase up to the fourth week of
in¯ammation (Figure 4B). The majority of MNC had migrated
by day 28 as determined by morphology (Figure 4D). However,
PMN were also present at this time-point (data not shown).
Chemokines and chemokine receptors in the granuloma
The mRNA expression of CXCR2 showed a single peak
maximal at day 3. Relatively high amounts of this mRNA were
also detected at day 7, after which values decreased rapidly
towards control (Figure 5A). Of the three potential CXCR2
Figure 3 Semi-quantitative analysis of cell population in the dierent skin layers and granulomatous tissue during CO/CFA
induced in¯ammation. Tissues (skin or granuloma) were embedded in historesin, stained and analysed as described in Methods.
Analysis could distinguish between mast cells, MNC, PMN and ®broblasts present in the dermis (A), adipose tissue (B), skeletal
muscle tissue (C) and granulomatous tissue (D). Values represent mean+s.e.mean of cell number counted in three dierent regions
of 1006100 mm2 area, ®ve distinct serial sections (1.5 mm) of four dierent mice.
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ligands tested, KC (CXCL1) and MIP-2, but not LIX
(CXCL5), mRNA were detected and found to be maximal at
day 3, in correspondence to the CXCR2 mRNA (Figure 5B).
The pro®le of CCR2 and CCR5 mRNA expression was
less clear, and changes were less pronounced (Figure 5C,E).
The mRNA for some putative ligands for these receptors was
also increased, though with some dierences. Figure 5D
shows MCP-1 (CCL2) mRNA being high at days 3 and 28,
whereas MCP-3 (CCL 7) mRNA highest values are measured
at days 14 and 28. MIP-1b (CCL4) and RANTES (CCL5)
follow a similar pattern of expression, with MIP-1û mRNA
being clearly highly expressed during the ®rst week of
in¯ammation (Figure 5F).
Chemokine protein expression within the granulomatous
tissue paralleled the detection of mRNA. KC (CXCL1) and
MIP-2 protein were clearly elevated within the ®rst week of
in¯ammationasdetectedbyELISA(Figure6A).MIP-1a (CCL3)
was maximally expressed at day 3 (Figure 6B), whereas MCP-1
(CCL2) levels increased in a time-dependent fashion,with values
above control skin samples at day 21 (Figure 6C). RANTES
(CCL5) protein expression increased gradually in a time-
dependent fashion with maximal values at day 28 (Figure 6D).
Immunohistochemistry for MIP-1a and MCP-1
The cell source of two chemokines that were expressed at
dierent stages of this experimental in¯ammatory reaction was
then investigated. In the granulomatous tissue of samples
collected at day 7 post CO/CFA injection, MIP-1a immunor-
eactivity was detected in ®broblasts (Figure 7A) and MNC
(Figure 7B). After the ®rst week of in¯ammation, the number
of positive cells decreased in accordance with the data obtained
by ELISA (data not shown). MCP-1 localization was studied in
correspondence of the peak of protein expression, i.e. at day 21
(Figure 6C). A part from some scattered MNC and ®broblasts
(Figure 7E), MCP-1 immuno-reactivity was predominantly
associated with mast cells (Figure 7D,F). The identity of this
cell type was also con®rmed by counter-staining with toluidine
blue (data not shown). No staining was visualized in sections
stained with pre-adsorbed antibody (Figure 7C).
Effect of neutralizing antisera to MIP-1a and MCP-1
Treatment of mice with the anti-MIP-1a serum did not
signi®cantly modi®ed the in¯ammatory response as measured
at day 7, with the exception of a reduction in MIP-1a contents
(Table 3). In contrast, animals treated with the anti-MIP-1a
serum displayed higher values for in¯ammatory parameters at
day 21, namely for MPO activity, NAG activity and MCP-1
contents (Table 3).
The anti-MCP-1 serum was tested only at day 21, since this
time-point corresponded to the peak of endogenous MCP-1
expression (see Figure 6c). Table 4 shows the data obtained,
with a signi®cant decrease (*40%) in NAG activity and a
reduction in the content of RANTES. This was associated with
a signi®cant increase in MPO values (Table 4).
Discussion
The granulomatous air-pouch has been previously employed
to study the pro®le of expression of pro-in¯ammatory and
Figure 4 Enzymatic activities and in®ltrating cells associated with
granulomatous tissue. (A) Time-course of MPO activity and (B)
NAG activity as measured in the granulomatous tissue. May-
Grumwald-Giemsa staining of historesin sections (1.5 mm) showing
(C) an intense PMN in¯ux on day 7 (arrows) and (D) the presence of
MNC (indicated by open arrows) on day 28. Values are mean+
s.e.mean of 410 mice per group, whereas pictures are representative
of three dierent mice *P50.05 vs control (non in¯amed) group. Bar,
20 mm.
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anti-in¯ammatory cytokines, mainly using an immunohisto-
chemistry strategy (Appleton et al., 1993). The interest in this
model stems from the morphological analogies between the
experimental granuloma and the pannus observed in the
joints of patients aected by rheumatoid arthritis, for
instance presence of resident macrophages and ®broblasts
(Kimura et al., 1985; 1986; Kasama et al., 1995). Injection of
CO/CFA initiates a complex in¯ammatory reaction. Based
on distinct patterns of expression, and on the appearance of
PMN and MNC into the granuloma, the existence of an
Figure 5 Time-course of mRNA chemokine and chemokine receptor expression during CO/CFA in¯ammation as determined by
TaqMan1 RT±PCR analysis. Quanti®cation of the following mRNA was made in granulomatous tissue samples. (A) CXCR2 and
(B) CXCR2 ligands; KC, MIP-2 and LIX. (C) CCR2 and (D) CCR2 ligands; MCP-1 and MCP-3; (E) CCR5 and (F) CCR5 ligands;
MIP-1b and RANTES. Values are fold increase of gene amount normalised against the 18S gene and expressed as mean+s.e.mean
of 410 mice per group. *P50.05 vs control (non in¯amed) skin.
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Figure 6 Chemokine protein levels during CO/CFA in¯ammation. (A) Granuloma content of KC and MIP-2, (B) MIP-1a, (C)
MCP-1 and (D) RANTES protein levels. Values are mean+s.e.mean of 410 mice per time-point, *P50.05 vs control (non
in¯amed) skin.
Table 3 Eect of the anti-MIP-1a polyclonal serum on selected markers of the granulomatous air-pouch in¯ammation
Marker of inflammation Anti-MIP-1a Non-immune
(units) serum rabbit serum
Day 7
Granuloma wet weight (mg) 345+41 (8) 488+54 (4)
MPO (mU mg protein71) 189+20 (8) 224+16 (4)
NAG (mmol mg protein71) 77+8 (8) 62+22 (4)
MIP-1a (pg mg protein71) 664+60 (8)* 1263+84 (4)
Day 21
Granuloma wet weight (mg) 273+84 (6) 264+32 (4)
MPO (mU mg protein71) 275+21 (6)* 139+22 (4)
NAG (nmol mg protein71) 87+6 (6)* 54+11 (4)
MCP-1 (pg mg protein71) 191+31 (6)* 123+21 (4)
RANTES (pg mg protein71) 4286+745 (6) 5187+316 (5)
Animals were treated with the mixture of CO/CFA at day 0, and with non-immune rabbit serum or with the anti-MIP-1a antiserum at
days 71, 1 and 4 (500 ml i.p. each time). Tissues were collected either at day 7 or day 21, and the dierent markers of in¯ammation
determined as described in Methods. Values shown are the mean value+s.e.mean of (n) mice per group. *P50.05 vs corresponding
value in the non-immune serum group.
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Figure 7 Localization of MIP-1a and MCP-1 in the granulomatous tissue. Cryostat sections (10 mm) showing (A) MIP-1a staining
in ®broblasts (arrow) and (B) in MNC (likely to be macrophages, arrows). (C) Negative control of pre-absorbed MCP-1 polyclonal
antibody on paran embedded sections (3 mm). (D) Immunoreactivity for MCP-1 in ®broblasts and mast cells localized mainly in
dermis and some scattered mast cells in the granuloma layer. (E) High magni®cation of ®broblasts and MNC cells MCP-1 positive
detected in dermis in the rectangular ®eld in (D). (F) High magni®cation of mast cells MCP-1 positive observed in dermis layer
indicated by the arrowhead in (D). Bar, 20 mm for panels A, B, E and F; bar, 50 mm panel D and 100 mm panel C.
Table 4 Eect of the anti-MCP-1 polyclonal serum on selected markers of the granulomatous air-pouch in¯ammation
Marker of inflammation Anti-MCP-1 Non-immune
(units) serum rabbit serum
Granuloma wet weight (mg) 318+53 (8) 287+69 (5)
MPO (mU mg protein71) 203+18 (8)* 101+14 (5)
NAG (nmol mg protein71) 158+19 (8)* 276+21 (5)
MCP-1 (pg mg protein71) 101+25 (8) 83+25 (5)
RANTES (pg mg protein71) 1722+189 (8)* 2814+398 (5)
Animals were treated with the mixture of CO/CFA at day 0, and with non-immune rabbit serum or with the anti-MCP-1 antiserum at
days 10 and 14 (0.5 ml i.p. each time). Tissues were collected either at day 7 or day 21, and the dierent markers of in¯ammation
determined as described in Methods. Values shown are the mean value+s.e.mean of (n) mice per group. * P50.05 vs corresponding
value in the non-immune serum group.
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acute phase (maximal within the ®rst week) and of repair
phase (from day 21 onwards) has been proposed (Appleton et
al., 1993).
Initially, we validated the model. We could demonstrate
the presence of layers of granulomatous tissue from day 3,
with a time-dependent progressive thickening. Day 7
corresponded to the time-point of maximal PMN in®ltration
and the presence of characteristic signs of an intense
in¯ammatory reaction, including mast cell degranulation. It
has been demonstrated that this stage presents a high
incidence of neo-vessel formation (angiogenesis) (Colville-
Nash et al., 1995). These events occur also at the skin level,
with leukocyte in®ltration into the derma and hypoderma.
However, quantitatively, the major portion (480%) of
blood-borne cells migrated into the granuloma.
The existence of a PMN in¯ux within the ®rst week was
con®rmed by measurement of MPO activity. Assessment of
this enzyme has often been used to determine tissue
in®ltration by PMN (Mullane et al., 1985). MPO measure-
ment coupled to histology and the expression of PMN
selective chemokines (see below) suggest that the ®rst week of
this in¯ammatory reaction was predominantly characterized
by PMN accumulation. The striking expression of CXCR2 in
the granuloma at days 3 and 7 con®rms this suggestion, since
PMN express high levels of this receptor (Murphy et al.,
1996).
CXCR2 mRNA expression was paralleled by expression of
its ligands both at the mRNA and protein level. In particular,
MIP-2 and KC were strongly expressed within the ®rst week
of in¯ammation, whereas the recently discovered CXC
chemokine LIX was not. Dierences in time expression of
these three chemokines have been reported during experi-
mental endotoxemia (Rovai et al., 1998), but are unlikely to
explain the lack of detection of LIX mRNA in this model. A
few days of delay were observed in terms of peak of mRNA
and protein expression for MIP-2 and KC: this is not
surprising and may indicate the existence of mechanism(s) for
controlling mRNA translation. We have observed a similar
feature for granuloma expression of the anti-in¯ammatory
protein annexin-1 (unpublished data). A human analogue of
the CXC murine chemokine KC (likely to be gro-a; Zlotnik
& Yoshie, 2000) is detected in synovial ¯uids of patients
aected by rheumatoid arthritis, with synovial ®broblasts
being the major cell source (Koch et al., 1995): it is possible
that KC-related chemokines play a functional role in
attracting human PMN into the injured joints.
A dierence in the time course of expression between the
two CC chemokines MIP-1a and MCP-1 was observed in
this model of chronic in¯ammation. MIP-1 a seems to play
an important role in human rheumatoid arthritis (Koch et
al., 1995), and its mRNA is abundantly expressed in the
joints during mouse collagen-induced arthritis (Kasama et
al., 1995; Kunkel et al., 1996). This CC chemokine acts as a
chemoattractant on both PMN and MNC (DiPietro et al.,
1998; Ajuebor et al., 1999), however the pro®le of expression
in this model indicates a major eect upon the PMN. In
addition, MIP-1a activates mast cells (Alam et al., 1992) and
therefore may contribute to the degranulation of this cell
type observed from day 3 post-CO/CFA injection. In view
of the pivotal role that mast cell-derived products play in
the recruitment of PMN (Granger & Kubes, 1994), it is
tempting to propose a model in which MIP-1a plays central
role in the ®rst week of in¯ammation (the so-called `acute
phase' of Appleton et al., 1993). Other chemokines such as
KC may also have a prominent role in producing mast cell
activation (Harris et al., 1996). The neutralization experi-
ments however indicate that if MIP-1a plays a pro-
in¯ammatory role within day 7, it is clear that its role can
be taken over by other mediators or chemokines. The set of
functional data indicates, rather, that early MIP-1a expres-
sion possesses an anti-in¯ammatory role on the progression
of the granulomatous in¯ammation. It is of interest that
MIP-1a expression has been associated with murine wound
repair (DiPietro et al., 1998).
MCP-1 expression was clearly associated with this latter
phase characterized by deposition of collagen ®bres, ®bro-
blast proliferation and ®brosis (Appleton et al., 1993;
Colville-Nash et al., 1995). The existence of mechanism(s)
regulating mRNA translation, or the potential need for
accessory factors, are likely to be involved for MCP-1 since a
modest increase in MCP-1 mRNA was detected at day 3, but
the protein was not detectable by ELISA. The second peak of
MCP-1 mRNA was linked to the presence of MCP-1 protein,
from day 14 onward. RANTES mRNA and protein followed
a similar pro®le of expression.
At variance from the hypothesis of Appleton et al. (1993),
who proposed the existence of a process of resolution from
day 14 onward, in our hands many parameters of
in¯ammation were still elevated or present even at day 28.
In fact, whereas low values were measured at day 21 for
several parameters, including PMN and MPO activity,
chemokine and chemokine receptor mRNA, clear signs of
an active in¯ammatory response were measured at day 28:
mast cell degranulation and PMN in®ltration were clearly
seen in the granuloma. This was also associated to high MPO
activity, besides the expected high value for NAG activity. It
is now clear that monocytes also contain MPO positive
granules, and therefore can contribute to tissue appearance of
this enzymatic activity (Dallegri & Ottonello, 1997; Korthuis
et al., 1994; Marquez & Dunford, 1997). Therefore, in
contrast to previous publications on this model of granulo-
ma, we would propose the presence of a process of ®brosis
characterizing the second phase of in¯ammation from day 14
onwards. Importantly, MCP-1 has been shown to be a potent
pro-®brotic chemokine (Hogaboam et al., 1999), whereas
RANTES does not share this activity (Lloyd et al., 1997).
Together with a published study (Appleton et al., 1993), we
propose a ®brotic alteration of the granuloma driven initially
by transforming growth factor-b (that peaks at day 14), and
subsequently by MCP-1. In this scenario, RANTES may
contribute in an as yet unknown manner to the chroniciza-
tion of the in¯ammatory reaction, as recently shown in an
experimental model of in¯ammatory bowel disease (Ajuebor
et al., 2001).
The experiment of neutralization supports, to our opinion,
this hypothesis. The anti-MCP-1 antiserum reduced NAG
activity and RANTES values, and elevated MPO activity, as
measured at day 21. It may be proposed, then, that MCP-1
and possibly RANTES recruit monocyte/macrophages at this
time-point. Importantly, NAG is expressed at higher levels by
dierentiated macrophages (de Moulder et al., 1983). The
higher MPO values observed in the anti-MCP-1 group may
indicate a lower degree of removal of migrated PMN caused
by the lower number of macrophages.
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Finally, the availability of two anti-sera validated for
detection of MIP-1a and MCP-1 in tissues allowed us to
monitor the cellular localization of these chemokines at the
peak of their expression. Monocyte/macrophages and ®bro-
blasts were positive for MIP-1a in the 7 day-granuloma. This
®nding is in agreement with other experimental models of
in¯ammation (Chensue et al., 1996; di Pietro et al., 1998;
Kunkel et al., 1989; Standiford et al., 1993). MCP-1 was
predominantly expressed by mast cells located in the
granuloma as well as in the surrounding skin layers. We
believe this is an important observation, and linked to other
studies (Tailor et al., 1999) it suggests mast cells as a major
source of CXC and CC chemokines in in¯ammation. With
respect to this speci®c chemokine, we have recently found
that mouse peritoneal mast cells are the major producers of
MCP-1 during acute peritonitis (Ajuebor et al., 1999). It
therefore seems that mast cells have the capacity to synthesize
several in¯ammatory mediators, including chemokines, and
therefore have a prominent role in many forms of
in¯ammation. Importantly, cell responsiveness to MCP-1 is
altered during experimental chronic in¯ammation (Johnston
et al., 1999). If this phenomenon also occurs in our model of
granulomatous air-pouch, then we propose that mast cell
derived MCP-1 may be responsible for the delayed (421
days) neutrophil recruitment.
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